Annual Total Expenses
$237.66 M
-$44.67 M-15.82%
December 31, 2023
Summary
- As of February 7, 2025, HRTX annual total expenses is $237.66 million, with the most recent change of -$44.67 million (-15.82%) on December 31, 2023.
- During the last 3 years, HRTX annual total expenses has fallen by -$79.14 million (-24.98%).
- HRTX annual total expenses is now -33.37% below its all-time high of $356.66 million, reached on December 31, 2019.
Performance
HRTX Total Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Total Expenses
$37.27 M
-$5.20 M-12.25%
September 30, 2024
Summary
- As of February 7, 2025, HRTX quarterly total expenses is $37.27 million, with the most recent change of -$5.20 million (-12.25%) on September 30, 2024.
- Over the past year, HRTX quarterly total expenses has dropped by -$5.20 million (-12.25%).
- HRTX quarterly total expenses is now -61.30% below its all-time high of $96.30 million, reached on March 31, 2019.
Performance
HRTX Quarterly Total Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Total Expenses Formula
Total Expenses = Cost of Goods Sold + Operating Expenses + Non Operating Expenses
HRTX Total Expenses Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -15.8% | -12.3% |
| 3 y3 years | -25.0% | -50.3% |
| 5 y5 years | -9.1% | -51.9% |
HRTX Total Expenses Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -21.9% | at low | -56.9% | at low |
| 5 y | 5-year | -33.4% | at low | -60.5% | at low |
| alltime | all time | -33.4% | +4470.4% | -61.3% | +1055.6% |
Heron Therapeutics Total Expenses History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $37.27 M(-12.2%) |
| Jun 2024 | - | $42.47 M(+7.6%) |
| Mar 2024 | - | $39.47 M(-11.2%) |
| Dec 2023 | $237.66 M(-15.8%) | $44.45 M(-21.1%) |
| Sep 2023 | - | $56.36 M(-24.0%) |
| Jun 2023 | - | $74.17 M(+18.3%) |
| Mar 2023 | - | $62.68 M(+24.4%) |
| Dec 2022 | $282.33 M(-7.2%) | $50.38 M(-26.4%) |
| Sep 2022 | - | $68.44 M(-11.3%) |
| Jun 2022 | - | $77.13 M(-10.7%) |
| Mar 2022 | - | $86.38 M(+16.4%) |
| Dec 2021 | $304.17 M(-4.0%) | $74.19 M(-1.0%) |
| Sep 2021 | - | $74.94 M(-9.6%) |
| Jun 2021 | - | $82.91 M(+14.9%) |
| Mar 2021 | - | $72.13 M(-11.9%) |
| Dec 2020 | $316.80 M(-11.2%) | $81.90 M(+4.5%) |
| Sep 2020 | - | $78.35 M(-0.1%) |
| Jun 2020 | - | $78.42 M(+0.4%) |
| Mar 2020 | - | $78.13 M(-17.3%) |
| Dec 2019 | $356.66 M(+36.4%) | $94.44 M(+21.9%) |
| Sep 2019 | - | $77.48 M(-12.4%) |
| Jun 2019 | - | $88.44 M(-8.2%) |
| Mar 2019 | - | $96.30 M(+20.1%) |
| Dec 2018 | $261.41 M(+16.0%) | $80.16 M(+30.2%) |
| Sep 2018 | - | $61.57 M(+9.7%) |
| Jun 2018 | - | $56.13 M(-11.7%) |
| Mar 2018 | - | $63.56 M(-11.7%) |
| Dec 2017 | $225.32 M(+30.9%) | $71.94 M(+44.2%) |
| Sep 2017 | - | $49.89 M(-1.3%) |
| Jun 2017 | - | $50.56 M(-4.5%) |
| Mar 2017 | - | $52.93 M(+10.1%) |
| Dec 2016 | $172.19 M(+77.7%) | $48.08 M(+0.7%) |
| Sep 2016 | - | $47.73 M(+10.8%) |
| Jun 2016 | - | $43.07 M(+29.3%) |
| Mar 2016 | - | $33.31 M(+7.3%) |
| Dec 2015 | $96.92 M(+30.0%) | $31.06 M(+38.1%) |
| Sep 2015 | - | $22.49 M(-2.3%) |
| Jun 2015 | - | $23.01 M(+13.0%) |
| Mar 2015 | - | $20.36 M(+4.4%) |
| Dec 2014 | $74.56 M(+36.9%) | $19.50 M(+2.9%) |
| Sep 2014 | - | $18.95 M(+0.9%) |
| Jun 2014 | - | $18.79 M(+8.5%) |
| Mar 2014 | - | $17.32 M(+25.2%) |
| Dec 2013 | $54.46 M(+128.5%) | $13.83 M(+9.2%) |
| Sep 2013 | - | $12.66 M(-16.7%) |
| Jun 2013 | - | $15.21 M(+19.3%) |
| Mar 2013 | - | $12.75 M(+47.8%) |
| Dec 2012 | $23.83 M(+103.5%) | $8.63 M(+42.5%) |
| Sep 2012 | - | $6.05 M(+38.2%) |
| Jun 2012 | - | $4.38 M(-8.2%) |
| Mar 2012 | - | $4.77 M(+15.8%) |
| Dec 2011 | $11.71 M(+4.2%) | $4.12 M(+0.7%) |
| Sep 2011 | - | $4.09 M(+128.3%) |
| Jun 2011 | - | $1.79 M(+4.7%) |
| Mar 2011 | - | $1.71 M(-10.6%) |
| Dec 2010 | $11.23 M(-2.3%) | $1.91 M(-3.7%) |
| Sep 2010 | - | $1.99 M(-53.0%) |
| Jun 2010 | - | $4.22 M(+35.8%) |
| Mar 2010 | - | $3.11 M(+40.1%) |
| Dec 2009 | $11.50 M(-51.7%) | $2.22 M(-4.6%) |
| Sep 2009 | - | $2.33 M(-41.4%) |
| Jun 2009 | - | $3.97 M(+33.5%) |
| Mar 2009 | - | $2.98 M(-22.7%) |
| Dec 2008 | $23.81 M(-1.0%) | $3.85 M(-39.3%) |
| Sep 2008 | - | $6.34 M(-0.9%) |
| Jun 2008 | - | $6.40 M(-11.3%) |
| Mar 2008 | - | $7.22 M(-9.2%) |
| Dec 2007 | $24.05 M(+27.5%) | $7.95 M(+48.4%) |
| Sep 2007 | - | $5.36 M(+15.6%) |
| Jun 2007 | - | $4.63 M(-24.6%) |
| Mar 2007 | - | $6.15 M(+7.4%) |
| Dec 2006 | $18.86 M | $5.73 M(+45.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2006 | - | $3.95 M(-17.6%) |
| Jun 2006 | - | $4.79 M(+8.8%) |
| Mar 2006 | - | $4.40 M(+6.8%) |
| Dec 2005 | $13.86 M(-5.8%) | $4.12 M(+29.8%) |
| Sep 2005 | - | $3.17 M(-18.6%) |
| Jun 2005 | - | $3.90 M(+46.1%) |
| Mar 2005 | - | $2.67 M(-30.1%) |
| Dec 2004 | $14.72 M(+28.4%) | $3.82 M(+11.8%) |
| Sep 2004 | - | $3.42 M(-8.3%) |
| Jun 2004 | - | $3.73 M(-0.9%) |
| Mar 2004 | - | $3.76 M(+30.7%) |
| Dec 2003 | $11.46 M(+17.9%) | $2.88 M(+14.9%) |
| Sep 2003 | - | $2.50 M(-19.3%) |
| Jun 2003 | - | $3.10 M(+4.1%) |
| Mar 2003 | - | $2.98 M(+89.6%) |
| Dec 2002 | $9.72 M(-8.2%) | $1.57 M(-43.6%) |
| Sep 2002 | - | $2.79 M(-4.5%) |
| Jun 2002 | - | $2.92 M(+29.2%) |
| Mar 2002 | - | $2.26 M(-21.8%) |
| Dec 2001 | $10.60 M(+38.1%) | $2.89 M(-0.5%) |
| Sep 2001 | - | $2.90 M(+15.0%) |
| Jun 2001 | - | $2.52 M(+10.4%) |
| Mar 2001 | - | $2.28 M(-13.3%) |
| Dec 2000 | $7.67 M(+19.9%) | $2.63 M(+48.1%) |
| Sep 2000 | - | $1.78 M(-5.5%) |
| Jun 2000 | - | $1.88 M(+30.2%) |
| Mar 2000 | - | $1.45 M(-10.7%) |
| Dec 1999 | $6.40 M(+23.1%) | $1.62 M(-1.3%) |
| Sep 1999 | - | $1.64 M(-61.8%) |
| Jun 1999 | - | $4.30 M(+2.4%) |
| Mar 1999 | - | $4.20 M(-207.7%) |
| Dec 1998 | $5.20 M(-71.6%) | -$3.90 M(-186.7%) |
| Sep 1998 | - | $4.50 M(-6.3%) |
| Jun 1998 | - | $4.80 M(+11.6%) |
| Mar 1998 | - | $4.30 M(-8.5%) |
| Dec 1997 | $18.30 M(-32.7%) | $4.70 M(+6.8%) |
| Sep 1997 | - | $4.40 M(-10.2%) |
| Jun 1997 | - | $4.90 M(+11.4%) |
| Mar 1997 | - | $4.40 M(-35.3%) |
| Dec 1996 | $27.20 M(+10.1%) | $6.80 M(+6.3%) |
| Sep 1996 | - | $6.40 M(-11.1%) |
| Jun 1996 | - | $7.20 M(+4.3%) |
| Mar 1996 | - | $6.90 M(+4.5%) |
| Dec 1995 | $24.70 M(-0.8%) | $6.60 M(+26.9%) |
| Sep 1995 | - | $5.20 M(-22.4%) |
| Jun 1995 | - | $6.70 M(+11.7%) |
| Mar 1995 | - | $6.00 M(+25.0%) |
| Dec 1994 | $24.90 M(-17.8%) | $4.80 M(-22.6%) |
| Sep 1994 | - | $6.20 M(-13.9%) |
| Jun 1994 | - | $7.20 M(+2.9%) |
| Mar 1994 | - | $7.00 M(-9.1%) |
| Dec 1993 | $30.30 M(+121.2%) | $7.70 M(+13.2%) |
| Sep 1993 | - | $6.80 M(-15.0%) |
| Jun 1993 | - | $8.00 M(+73.9%) |
| Mar 1993 | - | $4.60 M(0.0%) |
| Dec 1992 | $13.70 M(+101.5%) | $4.60 M(+53.3%) |
| Sep 1992 | - | $3.00 M(-9.1%) |
| Jun 1992 | - | $3.30 M(+17.9%) |
| Mar 1992 | - | $2.80 M(+64.7%) |
| Dec 1991 | $6.80 M(-4.2%) | $1.70 M(0.0%) |
| Sep 1991 | - | $1.70 M(-10.5%) |
| Jun 1991 | - | $1.90 M(+18.8%) |
| Mar 1991 | - | $1.60 M(-15.8%) |
| Dec 1990 | $7.10 M(-12.3%) | $1.90 M(+11.8%) |
| Sep 1990 | - | $1.70 M(-10.5%) |
| Jun 1990 | - | $1.90 M(+18.8%) |
| Mar 1990 | - | $1.60 M(-15.8%) |
| Dec 1989 | $8.10 M(-3.6%) | $1.90 M(+18.8%) |
| Sep 1989 | - | $1.60 M(-33.3%) |
| Jun 1989 | - | $2.40 M |
| Dec 1988 | $8.40 M(+44.8%) | - |
| Dec 1987 | $5.80 M | - |
FAQ
- What is Heron Therapeutics annual total expenses?
- What is the all time high annual total expenses for Heron Therapeutics?
- What is Heron Therapeutics annual total expenses year-on-year change?
- What is Heron Therapeutics quarterly total expenses?
- What is the all time high quarterly total expenses for Heron Therapeutics?
- What is Heron Therapeutics quarterly total expenses year-on-year change?
What is Heron Therapeutics annual total expenses?
The current annual total expenses of HRTX is $237.66 M
What is the all time high annual total expenses for Heron Therapeutics?
Heron Therapeutics all-time high annual total expenses is $356.66 M
What is Heron Therapeutics annual total expenses year-on-year change?
Over the past year, HRTX annual total expenses has changed by -$44.67 M (-15.82%)
What is Heron Therapeutics quarterly total expenses?
The current quarterly total expenses of HRTX is $37.27 M
What is the all time high quarterly total expenses for Heron Therapeutics?
Heron Therapeutics all-time high quarterly total expenses is $96.30 M
What is Heron Therapeutics quarterly total expenses year-on-year change?
Over the past year, HRTX quarterly total expenses has changed by -$5.20 M (-12.25%)